DV Medical Supply, Inc.

2000 W 135th Street
Gardena, CA. 90249
US

800-438-2568

Meropenem Injection 500mg 20mL SDV 10/pk
Meropenem Injection 500mg 20mL SDV 10/pk

Meropenem Injection 500mg 20mL SDV 10/pk

In Stock.
Part Number:DVM-106111MK
MPN:
Manufacturer: Auromedics Pharmaceuticals

NDC:

55150-0207-20
You need to have an approved DV Med account to order this product.

Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of Age and Older Only)
Meropenem for Injection is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species.

Complicated Intra-abdominal Infections (Adult and Pediatric Patients)
Meropenem for Injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species.

Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only)
Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae.

Meropenem for Injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy

Related Items